Assessing in-vivo efficacy of experimental Alzheimer treatments in extensively validated, proprietary transgenic mouse models

Current drug development requires extensive characterization of many compounds and their detailed preclinical analysis. Transgenic mouse models of Alzheimer’s disease have proven valuable tools in the search for drugs and treatments that can slow down development of AD or eventually cure this devastating disorder.

reMYND’s CRO is a trusted partner to help our clients understand as fast as possible the therapeutic in-vivo effects of all experimental AD treatments. Our mission is to be a strategic partner for our clients and help our clients identify the most promising set-up to assess potential effects by contributing our extensive expertise.

• For all types of treatments (e.g., small molecules, vaccination)
• Using all routes of administration (e.g., oral gavage, ip, iv, sc, icv)
• With unique and proprietary animal models (APP-London, also in combination with PS1 or TAU)
• With a broad testing window
• With a very rapid response time
• With a guarantee that you can use the data without any restriction v-à-v the Elan patents covering AD mouse models